bioAffinity Technologies, Inc. (BIAFW)
BIAFWNASDAQ-CMBiotechnology: Commercial Physical & Biological Resarch
$0.1650
-0.0670 (-28.88%) today
Closed, Nov 10, 10:28 AM ET
- Market cap
- $274.3k
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.0501 to $0.9800
- Average volume
- –
- Previous close
- $0.2320
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.45m | $1.59m | $1.35m | $1.51m |
| Gross profit | $504.0k | $693.0k | $423.0k | $423.0k |
| Operating income | -$2.29m | -$3.14m | -$3.62m | -$3.33m |
| Net income | -$5.05m | -$3.14m | -$3.63m | -$3.37m |
Last four quarters: revenue $5.90m, margin -257.3%, free cash flow –
News
8 latest- Coya Therapeutics Reports Wider Q3 Loss; Expects Phase 2/3 ALSTARS ALS Data In Q2 2027 RTTNews · 9 minutes ago
- FDA Drug Approvals In October 2026 RTTNews · 10 minutes ago
- Humacyte Q3 Loss Narrows On Lower R&D Costs; Sees Symvess Sales At Least Doubling In Q4 RTTNews · 10 minutes ago
- Swarmer (SWMR) Q3 2026 Earnings Call TranscriptThe Motley Fool · 16 minutes ago
- Stocks Settle Lower on Fed Rate Hike FearsBarchart · 26 minutes ago
- Atossa Therapeutics Q3 Loss Narrows; Expects (Z)-Endoxifen IND Clearance In Early 2027 RTTNews · 43 minutes ago
- Duke Energy Florida To Develop Four Solar Sites By Mid-2028; Expects $1 Bln Savings For Customers RTTNews · 50 minutes ago
- CoreWeave Earnings: 3 Things Investors Need To KnowThe Motley Fool · 1 hour ago
The company
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- bioaffinitytech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.